Clearbridge's device can detect CTCs without antibodies

06/5/2013 |

Clearbridge BioMedics has introduced the ClearCell FX technology, which can detect circulating tumor cells without the need for antibodies or other labeling techniques, this article says. The system, co-developed with Cambridge Consultants, incorporates a tiny device called the CTChip FR that employs fluid dynamics to isolate CTCs from other cells in blood for further analysis.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC